Literature DB >> 17115697

Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine.

Pauli J Ojala1, Martin Hermansson, Martti Tolvanen, Kirsi Polvinen, Tia Hirvonen, Ulla Impola, Matti Jauhiainen, Pentti Somerharju, Jaakko Parkkinen.   

Abstract

Alpha-1 acid glycoprotein (AGP, orosomucoid), a major acute phase protein in plasma, displays potent cytoprotective and anti-inflammatory activities whose molecular mechanisms are largely unknown. Because AGP binds various exogenous drugs, we have searched for endogenous ligands for AGP. We found that AGP binds lysophospholipids in a manner discernible from albumin in several ways. First, mass spectrometric analyses showed that AGP isolated from plasma and serum contained lysophosphatidylcholine (LPC) enriched in mono and polysaturated acyl chains, whereas albumin contained mostly saturated LPC. Second, AGP bound LPC in a 1:1 molar ratio and with a higher affinity than free fatty acids, whereas albumin bound LPC in a 3:1 ratio but with a lower affinity than that of free fatty acids. Consequently, free fatty acids displaced LPC more avidly from albumin than from AGP. Competitive ligand displacement indicated the highest affinity for AGP to LPC20:4, 18:3, 18:1, and 16:0 (150-180 nM), lysophosphatidylserine (Kd 190 nM), and platelet activating factor (PAF) (Kd 235 nM). The high affinity of AGP to LPC in equilibrium was verified by stopped-flow kinetics, which implicated slow dissociation after fast initial binding, being consistent with an induced-fit mechanism. AGP also bound pyrene-labeled phospholipids directly from vesicles and more efficiently than albumin. AGP prevented LPC-induced priming and PAF-induced activation of human granulocytes, thus indicating scavenging of the cellular effects of the lipid ligands. The results suggest that AGP complements albumin as a lysophospholipid scavenging protein, particularly in inflammatory conditions when the capacity of albumin to sequester LPC becomes impaired.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17115697     DOI: 10.1021/bi061657l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging.

Authors:  Marta Gonzalez-Freire; Ruin Moaddel; Kai Sun; Elisa Fabbri; Pingbo Zhang; Mohammed Khadeer; Norman Salem; Luigi Ferrucci; Richard D Semba
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-01-01       Impact factor: 6.053

2.  Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation.

Authors:  Yun Sok Lee; Jin Woo Choi; Injae Hwang; Joo Won Lee; Jae Ho Lee; A Young Kim; Jin Young Huh; Young Jun Koh; Gou Young Koh; Hee Jung Son; Hiroaki Masuzaki; Kikuko Hotta; Assim A Alfadda; Jae Bum Kim
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

Review 3.  Do not let death do us part: 'find-me' signals in communication between dying cells and the phagocytes.

Authors:  C B Medina; K S Ravichandran
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

4.  Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production.

Authors:  Monika Riederer; Pauli J Ojala; Andelko Hrzenjak; Wolfgang F Graier; Roland Malli; Michaela Tritscher; Martin Hermansson; Bernhard Watzer; Horst Schweer; Gernot Desoye; Akos Heinemann; Sasa Frank
Journal:  J Lipid Res       Date:  2010-07-07       Impact factor: 5.922

5.  A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay.

Authors:  Jonathan K Fleming; Thomas R Glass; Steve J Lackie; Jonathan M Wojciak
Journal:  J Lipid Res       Date:  2016-07-21       Impact factor: 5.922

Review 6.  Autotaxin: structure-function and signaling.

Authors:  Anastassis Perrakis; Wouter H Moolenaar
Journal:  J Lipid Res       Date:  2014-02-18       Impact factor: 5.922

Review 7.  G2A and LPC: regulatory functions in immunity.

Authors:  Janusz H Kabarowski
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-19       Impact factor: 3.072

8.  Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy.

Authors:  Gabriela Schneider; Zachariah Payne Sellers; Ahmed Abdel-Latif; Andrew J Morris; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2014-07-17       Impact factor: 5.852

9.  Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease.

Authors:  Richard D Semba
Journal:  Adv Nutr       Date:  2020-07-01       Impact factor: 8.701

10.  Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein.

Authors:  Mohammad A K Azad; Johnny X Huang; Matthew A Cooper; Kade D Roberts; Philip E Thompson; Roger L Nation; Jian Li; Tony Velkov
Journal:  Biochem Pharmacol       Date:  2012-05-12       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.